Morgan Stanley Starts Biogen (BIIB) at Overweight
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.83 -0.39%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley initiates coverage on Biogen (NASDAQ: BIIB) with a Overweight. PT $140.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $117.78 yesterday.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $117.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- JPMorgan Assumes salesforce.com (CRM) at Overweight, 'Overblown Concerns'
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
